Develop Strategic Drug Pricing Models To Meet Federal And State Pricing Requirements And Ensure Transparency
The Pharmaceutical Drug Pricing Strategies Summit is designed to bring senior pricing and reimbursement leaders to discuss the future of federal and state pricing requirements, transparency regulations, and strategic drug pricing models.
Given the recent news headlines, Senate finance hearings, and the introduction of drug pricing transparency laws, drug pricing is under the national spotlight. The Pharmaceutical Drug Pricing Strategies Summit brings pricing and reimbursement leaders together to discuss the future of federal and state pricing requirements, transparency regulations, and strategic drug pricing models.
- Develop strategic drug pricing models to meet federal and state pricing requirements and ensure transparency
- Understand the Impact Of International Pricing Indexing on the US Pharmaceutical Drug Pricing
- Explore multi-stakeholder insights from manufacturers, insurers, and more on the future of drug price transparency and patient affordability
- Navigate Reimbursement Models for Medicare Part B and its impact on Medicare Drug Pricing
- Explore the use of Value-Based Pricing And Reimbursement Frameworks
- Examine Formulary Management Strategies to Deliver Value for List Price
Vice President, Lilly Diabetes, Senior Vice President, Connected Care and Insulins
Eli Lilly and Company
Former President and CEO, Medicaid Health Plans of America; Former EVP, strategy and External Relations
2019 Topic Areas Include:
Drug Price Transparency Laws and Policies
Medicare and Medicaid Drug Pricing Models
Value-Based Pricing and Reimbursement
Multi-stakeholder initiatives for patient access
In The News:
CMS announced a final rule that requires drug manufacturers to provide the list price for their products in direct-to-consumer ads.
A coalition of pharmaceutical companies sued HHS on the final ruling, arguing that advertising list prices is a violation of the first amendment and does not account for the differences among insurance plans.
A federal judge ruled listing drug prices in DTC ads are unlawful.
The Trump administration withdrew plans to eliminate drug price rebates.
A key senate committee unveiled a long-awaited package of drug pricing reforms that would cap how much drug makers can raise their prices in Medicare. It would also cap out-of-pocket expenses for Medicare beneficiaries and dramatically reform the program's prescription drug benefit.
HHS appealed against the federal court's decision to block the HHS final rule that required manufacturer's to disclose product list prices within DTC ads.
On Going- High drug prices will remain a centerpiece issue for politicians and Patients. Stay up to date with recent drug price transparency trends!
Call for Papers
Submit Abstract for Presentations
Pharmaceutical Drug Pricing Strategies Summit is now accepting abstract submissions for 2019!